Bosutinib (SKI-606) is an oral, dual Src/Abl tyrosine kinase inhibitor (TKI) approved for treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) that is resistant or intolerant to prior TKI therapy or for whom other TKIs are not appropriate choices. The objective of this review is to provide a longitudinal summary of toxicities that may arise during treatment with second-line or later bosutinib in patients with Ph+ chronic phase CML and to provide strategies for managing these toxicities. As bosutinib is not currently indicated for newly diagnosed CML, toxicities associated with first-line treatment are not reviewed. Recognition and optimal management of these toxicities can facilitate patient compliance and affect treatment outcomes.
Gambacorti Passerini, C. (2018). Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. ANNALS OF ONCOLOGY, 29(3), 578-587 [10.1093/annonc/mdy019].
Citazione: | Gambacorti Passerini, C. (2018). Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. ANNALS OF ONCOLOGY, 29(3), 578-587 [10.1093/annonc/mdy019]. | |
Tipo: | Articolo in rivista - Review Essay | |
Carattere della pubblicazione: | Scientifica | |
Presenza di un coautore afferente ad Istituzioni straniere: | No | |
Titolo: | Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. | |
Autori: | Gambacorti Passerini, C | |
Autori: | ||
Data di pubblicazione: | 2018 | |
Lingua: | English | |
Rivista: | ANNALS OF ONCOLOGY | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1093/annonc/mdy019 | |
Appare nelle tipologie: | 01 - Articolo su rivista |